Latest advanced prostate cancer Stories
SEATTLE and NEW YORK, Sept.
SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer.
SEATTLE and ATLANTA, Aug. 10 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced it has signed a lease agreement with Majestic Realty Co.
PARSIPPANY, N.J., Aug. 4 /PRNewswire/ -- Ferring Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved the trade name FIRMAGON(R) (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix.
KVISTGAARD, Denmark, June 1 /PRNewswire-FirstCall/ -- Detailed data from a randomized Phase 2 study with PROSTVAC(TM) were presented Saturday at the ASCO Annual Meeting in Orlando.
- Extended Median Survival by 4.1 Months and Increased 3-Year Survival by 38 Percent Compared to Placebo - - First Active Cellular Immunotherapy for Cancer to Prolong Survival - - Company to Host Webcast at 5:30 pm ET - CHICAGO and SEATTLE, April 28 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that its pivotal Phase 3 IMPACT study of PROVENGE(R) (sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of significantly improving overall...
FDA confirms durable pain palliation as an acceptable primary endpoint for a regulatory submission in support of market approval BOTHELL, WA, April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc.
- Study Meets Primary Endpoint Showing Statistically Significant Improvement in Overall Survival - - First Active Immunotherapy for Cancer to Prolong Survival - - Full Data to be Presented at Plenary Session at Upcoming AUA Annual Meeting - - Company to Host a Conference Call Today at 9:00 AM ET - SEATTLE, April 14 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that the pivotal Phase 3 IMPACT study of PROVENGE(R) (sipuleucel-T) in men with advanced prostate...
Omega-3 fatty acids appear protective against advanced prostate cancer and this effect may be modified by a genetic variant, U.S. researchers said.
For the first time, researchers have found something that can protect against advanced prostate cancer, and it's as simple as choosing the right things to eat.
- The governor of a province or people.